Skip to content
Porphyria News logo
  • About porphyria
    What is porphyria?
    Types
    Causes
    Symptoms
    Diagnosis
  • Treatments
    Approved treatments
  • News
  • Columns
    Hope in Action — Kristen Wheeden
    I’m Not Always Me — Kalyn Shelton
    Archived columns
    • One Thousand Flaming Swords — Claire Richmond
  • Advocacy partners
  • What can we help you find today?

August 23, 2023 News by Marisa Wexler, MS

Some AHP patients could receive Givlaari through BC PharmaCare

Certain people with acute hepatic porphyria (AHP) living in British Columbia may now get full coverage of Givlaari (givosiran) through BC PharmaCare. BC PharmaCare is a publicly funded program in British Columbia that helps residents of the Canadian province pay for certain prescription drugs and some other…

November 30, 2018 News by Alice Melao

Panhematin Approved in Canada to Treat Recurrent Attacks of Acute Intermittent Porphyria

Canadian patients who have recurrent attacks of acute intermittent porphyria (AIP) can now be treated with Recordati Rare Diseases Canada’ injectable hemin formulation, Panhematin. Health Canada has approved the use of Panhematin to reduce the production and buildup of toxic compounds in the body induced by…

Recent Posts

  • Case series illustrates challenges in getting diagnosis for AIP women
  • Rare dual diagnosis of lupus and PCT detailed in case report
  • Acute hepatic porphyria carriers need monitoring, study says
  • Feeling the fear that comes with my pohr-fear-ee-uh
  • Woman with HFE mutations gets PCT, sarcoidosis diagnosis
  • COVID-19 triggers AIP attack in woman, 31, case report says
  • Did mental health medications contribute to my AIP attack?
  • Givlaari safe, effective for acute hepatic porphyria patients: Study
  • For Global Porphyria Day, we asked patients to describe their pain


Envelope icon

Subscribe to our newsletter

Get regular updates to your inbox.

Bionews, Inc.

3 W Garden St
Suite 700
Pensacola, FL 32502
Website: bionews.com
Email: info@bionews.com
Phone: 1-800-936-1363

  • About Us
  • Leadership
  • Our Culture
  • Editorial Policy
  • Advertising Policy
  • Corrections Policy
  • Terms of Service
  • Privacy Policy
  • Careers
  • Contact Us
Disclaimer

This site is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Copyright © 2013-2025 All rights reserved.